InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
SAN FRANCISCO, July 23 /PRNewswire/ --
InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug…